Home > News > Tempo Hurries To Target Nanoparticle Combo Drugs
June 17th, 2007
Tempo Hurries To Target Nanoparticle Combo Drugs
Abstract:
Tempo Pharmaceuticals Inc. isn't wasting any time. Since its founding in late 2006, the Cambridge, Mass.-based company has raised Seed and Series A financings, licensed core technology, hired 15 employees, started partnership discussions and begun the process of translating its platform into a product fit for clinical trials.
Yet founder and CEO Alan Crane said the name Tempo refers not to the company's frenetic pace, but to the "temporal release" of multiple drugs from its Nanocell platform technology.
Source:
therapeuticsdaily.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Spinel-type sulfide semiconductors to operate the next-generation LEDs and solar cells For solar-cell absorbers and green-LED source October 3rd, 2025
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||